Increased plasma concentrations of endothelin in congestive heart failure in humans

R. J. Rodeheffer, Amir Lerman, D. M. Heublein, John C Jr. Burnett

Research output: Contribution to journalArticle

176 Citations (Scopus)

Abstract

Congestive heart failure is characterized by decreased cardiac output and increased peripheral vascular resistance. Endothelin, a peptide found in plasma, is a potent vasoconstrictor. We hypothesized that plasma concentrations of endothelin are increased in humans with congestive heart failure. Plasma samples were obtained from 71 healthy control subjects and 56 patients with congestive heart failure. The mean plasma concentration of endothelin, measured by radioimmunoassay, was 7.1 ± 0.1 pg/ml in the 71 normal control subjects but 12.6 ± 0.6 pg/ml in the 56 patients with heart failure (P = 0.001). To evaluate the relationship between circulating endothelin and clinical stage of congestive heart failure, we categorized patients into two groups-those with mild heart failure (New York Heart Association class I or II) and those with severe heart failure (class III or IV). Circulating endothelin in the 24 patients with mild disease was 11.1 ± 0.7 pg/ml, significantly higher than in normal subjects (P<0.001). Endothelin in the 32 patients with severe heart failure was 13.8 ± 0.9 pg/ml, a level significantly higher than that in the group with mild disease (P = 0.029). In the 56 patients with congestive heart failure, a negative correlation was found between plasma concentration of endothelin and left ventricular ejection fraction (r = -0.279; P = 0.037). These data demonstrate that the plasma concentration of endothelin is increased in humans with congestive heart failure and that the level correlates with the severity of disease. Endothelin may have a role in the increased vascular resistance in patients with chronic congestive heart failure.

Original languageEnglish (US)
Pages (from-to)719-724
Number of pages6
JournalMayo Clinic Proceedings
Volume67
Issue number8
StatePublished - 1992

Fingerprint

Endothelins
Heart Failure
Vascular Resistance
Vasoconstrictor Agents
Cardiac Output
Stroke Volume
Radioimmunoassay
Healthy Volunteers
Peptides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Increased plasma concentrations of endothelin in congestive heart failure in humans. / Rodeheffer, R. J.; Lerman, Amir; Heublein, D. M.; Burnett, John C Jr.

In: Mayo Clinic Proceedings, Vol. 67, No. 8, 1992, p. 719-724.

Research output: Contribution to journalArticle

@article{39efcfd99898449284dce40c0a674f9a,
title = "Increased plasma concentrations of endothelin in congestive heart failure in humans",
abstract = "Congestive heart failure is characterized by decreased cardiac output and increased peripheral vascular resistance. Endothelin, a peptide found in plasma, is a potent vasoconstrictor. We hypothesized that plasma concentrations of endothelin are increased in humans with congestive heart failure. Plasma samples were obtained from 71 healthy control subjects and 56 patients with congestive heart failure. The mean plasma concentration of endothelin, measured by radioimmunoassay, was 7.1 ± 0.1 pg/ml in the 71 normal control subjects but 12.6 ± 0.6 pg/ml in the 56 patients with heart failure (P = 0.001). To evaluate the relationship between circulating endothelin and clinical stage of congestive heart failure, we categorized patients into two groups-those with mild heart failure (New York Heart Association class I or II) and those with severe heart failure (class III or IV). Circulating endothelin in the 24 patients with mild disease was 11.1 ± 0.7 pg/ml, significantly higher than in normal subjects (P<0.001). Endothelin in the 32 patients with severe heart failure was 13.8 ± 0.9 pg/ml, a level significantly higher than that in the group with mild disease (P = 0.029). In the 56 patients with congestive heart failure, a negative correlation was found between plasma concentration of endothelin and left ventricular ejection fraction (r = -0.279; P = 0.037). These data demonstrate that the plasma concentration of endothelin is increased in humans with congestive heart failure and that the level correlates with the severity of disease. Endothelin may have a role in the increased vascular resistance in patients with chronic congestive heart failure.",
author = "Rodeheffer, {R. J.} and Amir Lerman and Heublein, {D. M.} and Burnett, {John C Jr.}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "719--724",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Increased plasma concentrations of endothelin in congestive heart failure in humans

AU - Rodeheffer, R. J.

AU - Lerman, Amir

AU - Heublein, D. M.

AU - Burnett, John C Jr.

PY - 1992

Y1 - 1992

N2 - Congestive heart failure is characterized by decreased cardiac output and increased peripheral vascular resistance. Endothelin, a peptide found in plasma, is a potent vasoconstrictor. We hypothesized that plasma concentrations of endothelin are increased in humans with congestive heart failure. Plasma samples were obtained from 71 healthy control subjects and 56 patients with congestive heart failure. The mean plasma concentration of endothelin, measured by radioimmunoassay, was 7.1 ± 0.1 pg/ml in the 71 normal control subjects but 12.6 ± 0.6 pg/ml in the 56 patients with heart failure (P = 0.001). To evaluate the relationship between circulating endothelin and clinical stage of congestive heart failure, we categorized patients into two groups-those with mild heart failure (New York Heart Association class I or II) and those with severe heart failure (class III or IV). Circulating endothelin in the 24 patients with mild disease was 11.1 ± 0.7 pg/ml, significantly higher than in normal subjects (P<0.001). Endothelin in the 32 patients with severe heart failure was 13.8 ± 0.9 pg/ml, a level significantly higher than that in the group with mild disease (P = 0.029). In the 56 patients with congestive heart failure, a negative correlation was found between plasma concentration of endothelin and left ventricular ejection fraction (r = -0.279; P = 0.037). These data demonstrate that the plasma concentration of endothelin is increased in humans with congestive heart failure and that the level correlates with the severity of disease. Endothelin may have a role in the increased vascular resistance in patients with chronic congestive heart failure.

AB - Congestive heart failure is characterized by decreased cardiac output and increased peripheral vascular resistance. Endothelin, a peptide found in plasma, is a potent vasoconstrictor. We hypothesized that plasma concentrations of endothelin are increased in humans with congestive heart failure. Plasma samples were obtained from 71 healthy control subjects and 56 patients with congestive heart failure. The mean plasma concentration of endothelin, measured by radioimmunoassay, was 7.1 ± 0.1 pg/ml in the 71 normal control subjects but 12.6 ± 0.6 pg/ml in the 56 patients with heart failure (P = 0.001). To evaluate the relationship between circulating endothelin and clinical stage of congestive heart failure, we categorized patients into two groups-those with mild heart failure (New York Heart Association class I or II) and those with severe heart failure (class III or IV). Circulating endothelin in the 24 patients with mild disease was 11.1 ± 0.7 pg/ml, significantly higher than in normal subjects (P<0.001). Endothelin in the 32 patients with severe heart failure was 13.8 ± 0.9 pg/ml, a level significantly higher than that in the group with mild disease (P = 0.029). In the 56 patients with congestive heart failure, a negative correlation was found between plasma concentration of endothelin and left ventricular ejection fraction (r = -0.279; P = 0.037). These data demonstrate that the plasma concentration of endothelin is increased in humans with congestive heart failure and that the level correlates with the severity of disease. Endothelin may have a role in the increased vascular resistance in patients with chronic congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0026634049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026634049&partnerID=8YFLogxK

M3 - Article

C2 - 1434909

AN - SCOPUS:0026634049

VL - 67

SP - 719

EP - 724

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -